# REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate Its Long Term Safety, Efficacy and Tolerability.

> **NCT04162470** · PHASE3 · TERMINATED · sponsor: **Regeneron Pharmaceuticals** · enrollment: 24 (actual)

## Conditions studied

- Paroxysmal Nocturnal Hemoglobinuria

## Interventions

- **DRUG:** REGN3918

## Key facts

- **NCT ID:** NCT04162470
- **Lead sponsor:** Regeneron Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-12-03
- **Primary completion:** 2022-04-07
- **Final completion:** 2022-04-07
- **Target enrollment:** 24 (ACTUAL)
- **Why stopped:** Business Decision
- **Last updated:** 2023-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04162470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04162470, "REGN3918 in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) to Evaluate Its Long Term Safety, Efficacy and Tolerability.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04162470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*